Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 34,300 shares, a decline of 32.2% from the May 30th total of 50,600 shares. Based on an average daily trading volume, of 37,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.2% of the shares of the company are sold short.

A number of analysts have recently weighed in on the stock. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. HC Wainwright set a $25.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, Zacks Investment Research cut shares of Inflarx from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. Capricor Therapeutics presently has a consensus rating of “Hold” and an average price target of $2.83.

Shares of Capricor Therapeutics stock traded up $0.10 on Thursday, reaching $3.37. The stock had a trading volume of 19,300 shares, compared to its average volume of 36,004. The business has a 50-day moving average price of $2.58. Capricor Therapeutics has a fifty-two week low of $2.53 and a fifty-two week high of $15.80. The company has a market capitalization of $11.39 million, a PE ratio of -0.65 and a beta of 1.70.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.03. Capricor Therapeutics had a negative net margin of 936.22% and a negative return on equity of 225.30%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts forecast that Capricor Therapeutics will post -3 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also: What does it mean to hold a stock in street name?

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.